Reata gets FDA orphan drug status for bardoxolone methyl to treat PAH

| April 13, 2015 | 0 Comments

Reata Pharmaceuticals, a US-based developer of breakthrough medicines, has secured orphan drug designation from the FDA Office of Orphan Products Development (OOPD) for bardoxolone methyl to treat pulmonary arterial hypertension (PAH).

Continue reading here:
Reata gets FDA orphan drug status for bardoxolone methyl to treat PAH

Tags: , , , , , , , , , , ,

Category: Uncategorized

About the Author ()

Leave a Reply